



CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE

12th Edition

CLSI M07™

Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically

CLSI M07 covers reference methods for determining minimal inhibitory concentrations of aerobic bacteria by broth macrodilution, broth microdilution, and agar dilution.

A standard for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

www.clsi.org

standard@clsi.org

Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically

Barbara L. Zimmer, PhD
Darcie E. Carpenter, PhD, CIC, CEM
German Esparza, MSc
Kevin Alby, PhD, D(ABMM)
Amelia Bhatnagar, MPH
Andrea L. Ferrell, MLS(ASCP)^{CM}

Laurie Flemming, SM, MT(ASCP)
Michael D. Huband, BS
Antonieta Jiménez-Pearson, MHA, PhD
Susan M. Kircher, MS, MT(ASCP)
Susan Weir, MPH, PhD
Rebecca Yee, PhD, D(ABMM)

Abstract

Clinical and Laboratory Standards Institute M07—*Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically* offers guidance for antimicrobial susceptibility testing that is indicated for any organism that contributes to an infectious process warranting antimicrobial chemotherapy, if its susceptibility cannot be reliably predicted from knowledge of the organism's identity. Susceptibility tests are most often indicated when the causative organism is thought to belong to a species capable of exhibiting resistance to commonly used antimicrobial agents.

Various laboratory methods can be used to measure the *in vitro* susceptibility of bacteria to antimicrobial agents. Clinical and Laboratory Standards Institute M07—*Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically* describes standard broth dilution (macrodilution and microdilution [the microdilution method described in CLSI M07 is the same methodology outlined in ISO 20776-1])¹ and agar dilution techniques, and it includes a series of procedures to standardize the way the tests are performed. The performance, applications, and limitations of the current CLSI-recommended methods are also described.

The supplemental information (CLSI M100² tables) used with this standard represents the most current information for drug selection, interpretation, and QC using the procedures standardized in CLSI M07.

Clinical and Laboratory Standards Institute (CLSI). *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically*. 12th ed. CLSI standard M07. ISBN 978-1-68440-226-7 [Print]; ISBN 978-1-68440-227-4 [Electronic]. Clinical and Laboratory Standards Institute, USA, 2024.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, and users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org.

If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:

P: +1.610.688.0100 **F:** +1.610.688.0700 **E:** customerservice@clsi.org **W:** www.clsi.org



Copyright ©2024 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, or other product or material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

To read CLSI’s full Copyright Policy, please visit our website at <https://clsi.org/terms-of-use/>.

Suggested Citation

CLSI. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically*. 12th ed. CLSI standard M07. Clinical and Laboratory Standards Institute; 2024.

Previous Editions:

June 1980, December 1982, June 1986, November 1988, April 1990, December 1993, January 1995, January 2000, January 2003, January 2006, January 2009, January 2012, January 2015, January 2018

CLSI M07-Ed12

ISBN 978-1-68440-226-7 (Print)

ISBN 978-1-68440-227-4 (Electronic)

ISBN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 44, Number 10

Committee Membership

Consensus Council

The Consensus Council sets priorities for CLSI standards development and votes on Final Draft documents to confirm that process requirements have been met. Consensus Council members are listed on the CLSI website: <https://clsi.org/standards-development/consensus-council/>

Subcommittee on Antimicrobial Susceptibility Testing

The Subcommittee on Antimicrobial Susceptibility Testing volunteers support the development and review of CLSI documents in specialty areas. Subcommittee members are listed on the CLSI website: <https://clsi.org/get-involved/volunteer-opportunities/subcommittees/>

Working Group on AST Disk Susceptibility and Dilution AST for Aerobes (CLSI M02 and CLSI M07)

Barbara L. Zimmer, PhD
Chairholder
Beckman Coulter, Inc.
USA

Amelia Bhatnagar, MPH
Centers for Disease Control and
Prevention
USA

Antonietta Jiménez-Pearson, MHA,
PhD
INCIENSA
Costa Rica

Darcie E. Carpenter, PhD, CIC, CEM
Vice-Chairholder
International Health Management
Associates, Inc.
USA

Andrea L. Ferrell, MLS(ASCP)^{CM}
BD
USA

Susan M. Kircher, MS, MT(ASCP)
BD Diagnostic Systems
USA

German Esparza, MSc
Vice-Chairholder
Proasecal SAS Colombia
Colombia

Laurie Flemming, SM, MT(ASCP)
National Institutes of Health,
Department of Laboratory Medicine
USA

Susan Weir, MPH, PhD
Global Microbiome Conservancy at
Openbiome
USA

Kevin Alby, PhD, D(ABMM)
UNC Hospital
USA

Michael S. Huband, BS
JMI Laboratories
USA

Rebecca Yee, PhD, D(ABMM)
The George Washington University
USA

Expert Panel on Microbiology

Expert panel volunteers support the development of CLSI documents by providing technical expertise in specialty areas. Expert panel members are listed by area of expertise on the CLSI website: <https://clsi.org/standards-development/expert-panels/>

Staff

Clinical and Laboratory Standards
Institute
USA

Laura Martin
Editorial Manager

Kristy L. Leirer, MS
Editor

Emily J. Gomez, MS, MLS(ASCP)^{CM}MB^{CM}
Program Manager

Catherine E.M. Jenkins, ELS
Editor

Lisa M.W. Walker, MS, ELS
Editor

Currently in preview, click buy full version

.....

iv

Contents

Abstract	i
Committee Membership	iii
Foreword	vii
Summary of CLSI Processes for Establishing Breakpoints and Quality Control Ranges	x
CLSI Subcommittee on Antimicrobial Susceptibility Testing Mission Statement	xi
Chapter 1: Introduction	1
1.1 Scope	2
1.2 Background	2
1.3 Standard Precautions	3
1.4 Terminology	4
Chapter 2: Indications for Performing Antimicrobial Susceptibility Tests	9
2.1 Selecting Antimicrobial Agents for Routine Testing and Reporting	10
2.2 Equivalent Agents	11
2.3 Suggested Guidelines for Routine and Selective Testing and Reporting	11
2.4 Antimicrobial Classes	14
Chapter 3: Broth and Agar Dilution Antimicrobial Susceptibility Testing Process	21
3.1 Antimicrobial Agents	23
3.2 Preparing Inoculum for Dilution Susceptibility Tests	25
3.3 Agar Dilution Procedure	27
3.4 Preparing Agar Dilution Plates	28
3.5 Broth Dilution Procedures (Macro Dilution and Microdilution)	31
3.6 Broth Macrodilution (Tube) Method	32
3.7 Broth Microdilution Method	33
3.8 Inoculum Suspension in Colony Counts	36
3.9 Determining Broth, Macro- or Microdilution End Points	37
3.10 Reporting Minimal Inhibitory Concentration Results	44
3.11 Special Considerations for Fastidious Organisms	44
3.12 Special Considerations for Detecting Resistance	48
3.13 Supplemental (Not Routine) Tests	57
3.14 Dilution Test Method Limitations	58
Chapter 4: Quality Control and Quality Assurance	61
4.1 Quality Control Purpose	62
4.2 Quality Control Responsibilities	62
4.3 Selecting Strains for Quality Control	63

Contents (Continued)

4.4 Maintaining and Testing Quality Control Strains64

4.5 Batch or Lot Quality Control65

4.6 Minimal Inhibitory Concentration Control Ranges65

4.7 Quality Control Testing Frequency (also refer to Appendix D and CLSI M100 Tables 5)65

4.8 Out-of-Range Results With Quality Control Strains and Corrective Action67

4.9 Reporting Patient Results When Out-of-Range Quality Control Results Are Observed70

4.10 Confirming Results When Patient Isolates Are Tested70

4.11 End-Point Interpretation Control71

Chapter 5: Conclusion 73

Chapter 6: Supplemental Information 75

 References76

 Appendix A. Preparation of Supplements, Media, and Reagents80

 Appendix B. Conditions for Dilution Antimicrobial Susceptibility Tests92

 Appendix C. Quality Control Strain Maintenance98

 Appendix D. Quality Control Protocol Flow Charts 100

 The Quality Management System Approach102

Foreword

The most current edition of CLSI M100,² an annually published volume of tables, is made available with this standard to ensure users are aware of the latest recommendations related to the methods described in CLSI M02,³ M07, and M11.⁴

Many other editorial and procedural changes in this edition of CLSI M07 resulted from Subcommittee on Antimicrobial Susceptibility Testing meetings held since 2018. Specific changes to the tables are summarized at the beginning of CLSI M100.² The most important changes in CLSI M07 are summarized below.

Overview of Changes

This standard replaces CLSI M07-Ed11, published in 2018. Several changes were made in this edition, including:

- **General:**
 - Revised information for testing and reporting to clarify relevant stakeholders
 - Revised nomenclature from “coagulase-negative staphylococci” (CoNS) to “staphylococci other than *Staphylococcus aureus*” (SOSA)
 - Revised nomenclature from “groups” to “tiers”
 - Revised nomenclature from “microdilution trays” to “microdilution panels”
- **Subchapter 1.4.1, Definitions:**
 - Added definitions for antimicrobial susceptibility testing, EDTA-modified carbapenem inactivation method, heteroresistance, inducible clindamycin resistance, and reference method
 - Deleted definition for D-zone test
- **Subchapter 1.4.2, Abbreviations and Acronyms:**
 - Added abbreviations for Mueller-Hinton fastidious and staphylococci other than *S. aureus*
 - Deleted abbreviations for coagulase-negative staphylococci and Mueller-Hinton broth
- **Subchapter 2.1, Selecting Antimicrobial Agents for Routine Testing and Reporting:**
 - Clarified and updated information on selecting antimicrobial agents for routine reporting
- **Subchapter 2.2, Equivalent Agents:**
 - Replaced former Subchapter 2.2, Routine Reports, with Subchapter 2.2, Equivalent Agents, with information on antimicrobial agents listed in CLSI M100² Tables 1
- **Subchapter 2.3, Suggested Guidelines for Routine and Selective Testing and Reporting:**
 - Revised suggested guidelines for routine and selective testing and reporting
 - Added new Table 2, Antimicrobial Agent Test and Report Tiers and Additional Considerations for Agents Listed in CLSI M100² Tables 1
 - Added new Table 3, Antimicrobial Agent Test and Report Designations and Additional Considerations for Agents Not Listed in CLSI M100² Tables 1
- **Subchapter 2.4, Antimicrobial Classes:**
 - Added new Table 4, Antimicrobial Agent Class Characteristics

- **Subchapter 3.1.3, Preparing Stock Solutions:**

- Added information stating that if the addition of a surfactant does not result in enhanced or reduced activity of the antimicrobial agent, a small amount of surfactant may be added to the stock solution

- **Subchapter 3.1.4, Number of Concentrations Tested:**

- Added information about having QC organisms that are on scale and cover most minimal inhibitory concentration ranges included in the concentration being tested

- **Subchapter 3.2.2, Colony Suspension Methods for Inoculum Preparation:**

- Revised colony suspension method for inoculum preparation

- **Subchapter 3.3, Agar Dilution Procedure:**

- Added information explaining that data have not been reviewed for all recent antimicrobial agents
- Added information stating that agar dilution is the only approved method for testing fosfomycin

- **Subchapter 3.5.1, Cation-Adjusted Mueller-Hinton Broth:**

- Added iron-depleted cation-adjusted Mueller-Hinton broth as the recommended medium for antimicrobial susceptibility testing of commonly isolated, rapidly growing, aerobic or facultative organisms when cefiderocol is tested

- **Subchapter 3.5.2, Broth Media for Testing Fastidious Organisms:**

- Added Mueller-Hinton fastidious broth to list of media that can be used for testing fastidious organisms

- **Subchapter 3.6.1, Preparing and Storing Diluted Antimicrobial Agents:**

- Deleted sentence stating that tubes from broth macrodilution can be saved for later use only if they have been frozen

- **Subchapter 3.6.2, Inoculum Preparation, Inoculation, and Incubation:**

- Added minimum final volume for broth macrodilution

- **Subchapter 3.7.1, Preparing and Storing Diluted Antimicrobial Agents:**

- Added information stating that an automated instrument or liquid handling device can be used
- Added information stating that the dilution scheme and volumes should be delivered according to the dispensing system

- **Subchapter 3.7.2, Inoculum Preparation, inoculation, and Incubation:**

- Added examples for determining appropriate colony-forming units for each microdilution well when the microdilution method is used

- **Subchapter 3.8.1, Performing Colony Counts From a 0.5 McFarland Suspension:**

- Added a step-action table for performing colony counts from a 0.5 McFarland suspension

- **Subchapter 3.8.2, Performing Colony Counts From a Microdilution Well or Macrodilution Tube:**

- Added new subchapter

- **Subchapter 3.9, Determining Broth Macro- or Microdilution End Points:**

- Added information on interpreting results
- Revised information about trailing growth and reading minimum inhibitory concentrations

- **Subchapter 3.11, Special Considerations for Fastidious Organisms:**
 - Added information on Mueller-Hinton fastidious broth for testing *Haemophilus influenzae*
- **Subchapter 3.12, Special Considerations for Detecting Resistance:**
 - Added information about *mecC* isolates to Subchapter 3.12.1.3.2, Reporting Oxacillin Resistance
 - Revised information on vancomycin-resistant *S. aureus* and vancomycin-intermediate *S. aureus* in Subchapter 3.12.1.4, Vancomycin Resistance in *S. aureus*
 - Revised information on vancomycin agar screen for *S. aureus* in Subchapter 3.12.1.4.2, Vancomycin Agar Screen for *S. aureus*
 - Revised information on AmpC enzymes in Subchapter 3.12.4.2, AmpC Enzymes
 - Revised information on carbapenemases in Subchapter 3.12.4.3, Carbapenemases (Carbapenem-Resistant Gram-Negative Bacilli)
 - Deleted former Subchapter 3.12.1.6, Linezolid Resistance
 - Renumbered former Table 2, Methods for Detecting Oxacillin Resistance in Staphylococci, as Table 6, Methods or Targets for Detection of Methicillin (Oxacillin)-Resistant *Staphylococcus* spp., and revised incubation times and methods
 - Renumbered former Table 3, Procedural Recommendations for Detecting Oxacillin Resistance in Staphylococci, as Table 7, Procedural Recommendations for Detection of Methicillin (Oxacillin)-Resistant *Staphylococcus* spp.
- **Subchapter 3.14.3, Development of Resistance and Testing Repeat Isolates:**
 - Revised information on development of resistance
- **Subchapter 4.3, Selecting Strains for Quality Control:**
 - Added recommendation for using additional or supplemental QC strains with end points covering as many drug concentrations on the panel as possible
- **Appendix A, Preparation of Supplements, Media, and Reagents:**
 - Added new section A3.3, Iron-Depleted Cation-Adjusted Mueller-Hinton Broth
 - Added new section A3.5, Mueller-Hinton Fastidious Broth
- **Appendix B, Conditions for Dilution Antimicrobial Susceptibility Tests:**
 - Table B1, Conditions for Dilution Antimicrobial Susceptibility Tests for Nonfastidious Organisms
 - Added iron-depleted cation-adjusted Mueller-Hinton broth (cefiderocol) as an acceptable medium for testing some nonfastidious organisms
 - Added water as an acceptable medium for preparing 0.5 McFarland inoculum for testing nonfastidious organisms
 - Table B2, Conditions for Dilution Antimicrobial Susceptibility Tests for Fastidious Organisms
 - Added Mueller-Hinton fastidious agar as an acceptable medium for testing for *H. influenzae* and *Streptococcus pneumoniae*

Summary of CLSI Processes for Establishing Breakpoints and Quality Control Ranges

The Clinical and Laboratory Standards Institute (CLSI) is an international, voluntary, not-for-profit, interdisciplinary, standards-developing, and educational organization accredited by the American National Standards Institute that develops and promotes the use of consensus-developed standards and guidelines within the health care community. These consensus standards and guidelines are developed in an open and consensus-seeking forum to cover critical areas of diagnostic testing and patient health care. CLSI is open to anyone or any organization that has an interest in diagnostic testing and patient care. Information about CLSI can be found at www.clsi.org.

The CLSI Subcommittee on Antimicrobial Susceptibility Testing reviews data from a variety of sources and studies (eg, *in vitro*, pharmacokinetics/pharmacodynamics, and clinical studies) to establish antimicrobial susceptibility test methods, breakpoints, and QC parameters. The details of the data necessary to establish breakpoints, QC parameters, and how the data are presented for evaluation are described in CLSI M23.⁵

Over time, a microorganism’s susceptibility to an antimicrobial agent may decrease, resulting in a lack of clinical efficacy and/or safety. In addition, microbiological methods and QC parameters may be refined to ensure more accurate and better performance of susceptibility test methods. Because of these types of changes, CLSI continually monitors and updates information in its documents. Although CLSI standards and guidelines are developed using the most current information available at the time, the field of science and medicine is always changing; therefore, standards and guidelines should be used in conjunction with clinical judgment, current knowledge, and clinically relevant laboratory test results to guide patient treatment.

Additional information, updates, and changes in this standard are found in the meeting summary minutes of the CLSI Subcommittee on Antimicrobial Susceptibility Testing at <https://clsi.org/meetings/ast-file-resources/>.

CLSI Subcommittee on Antimicrobial Susceptibility Testing Mission Statement

The CLSI Subcommittee on Antimicrobial Susceptibility Testing is composed of representatives from the professions, government, and industry, including microbiology laboratories, government agencies, health care providers and educators, and pharmaceutical and diagnostic microbiology industries. Using the CLSI voluntary consensus process, the subcommittee develops standards that promote accurate antimicrobial susceptibility testing and appropriate reporting. The mission of the CLSI Subcommittee on Antimicrobial Susceptibility Testing is to:

- Develop standard reference methods for antimicrobial susceptibility tests.
- Provide quality control parameters for standard test methods.
- Establish breakpoints and interpretive categories for the results of standard antimicrobial susceptibility tests and provide epidemiological cutoff values when breakpoints are not available.
- Provide suggestions for testing and reporting strategies that are clinically relevant and cost-effective.
- Continually refine standards and optimize detection of emerging resistance mechanisms through development of new or revised methods, breakpoints, and QC parameters.
- Educate users through multimedia communication of standards and guidelines.
- Foster a dialogue with users of these methods and those who apply them.

The ultimate purpose of the subcommittee’s mission is to provide useful information to enable laboratories to assist the clinician in the selection of appropriate antimicrobial therapy for patient care. The standards and guidelines are meant to be comprehensive and to include all antimicrobial agents for which the data meet established CLSI guidelines. The values that guide this mission are quality, accuracy, fairness, timeliness, teamwork, consensus, and trust.

NOTE: The content of this standard is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

KEY WORDS		
agar dilution	broth dilution	broth microdilution
antimicrobial susceptibility	broth macrodilution	minimal inhibitory concentration

This page is intentionally left blank.

Chapter 1

Introduction

Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically

1 Introduction

1.1 Scope

This standard describes standard broth (macrodilution and microdilution) and agar dilution methods for determining *in vitro* susceptibility to antimicrobial agents for bacteria that grow aerobically and includes:

- Broth and agar dilution test preparation
- Testing conditions, including inoculum preparation and standardization, incubation time, and incubation temperature
- Results interpretation
- QC procedures
- Dilution test method limitations

To assist the medical laboratory, recommendations are provided for selecting antimicrobial agents for routine testing and reporting.

Standards for testing the *in vitro* antimicrobial susceptibility of bacteria that grow aerobically using the antimicrobial disk testing method are found in CLSI M02.³ Standards for testing the *in vitro* antimicrobial susceptibility of bacteria that grow anaerobically are found in CLSI M11.⁴ Guidelines for standardized antimicrobial susceptibility testing (AST) of infrequently isolated or fastidious bacteria that are not included in CLSI M02,³ M07, or M11⁴ are available in CLSI M45.⁶ The AST methods provided in this standard can be used in laboratories around the world, including but not limited to:

- Medical laboratories
- Public health laboratories
- Research laboratories
- Food laboratories
- Environmental laboratories

1.2 Background

Either broth or agar dilution methods may be used to quantitatively measure the *in vitro* activity of an antimicrobial agent against a given bacterial isolate. To perform the tests, a series of tubes or microtiter wells with a broth (for broth dilution) or agar medium (for agar dilution) are prepared to which various concentrations of the antimicrobial agents are added. The tubes or microtiter wells (for broth dilution) or plates (for agar dilution) are then inoculated with a standardized suspension of the test organism. After incubating for the appropriate time interval, the tests are read, the minimal inhibitory concentration (MIC) is determined, and the results are analyzed using approved breakpoints. The final result is significantly influenced by methodology, which must be carefully controlled if reproducible results (intra- and interlaboratory) are to be achieved.